Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome. It is also developing OV935, a drug candidate that is in Phase Ib/IIa trial for rare epileptic encephalopathies; preclinical-stage compounds for rare epilepsy disorders; and OV102, an intravenous formulation for indications in the clinical setting. The company has collaboration agreement with Takeda Pharmaceutical Company Limited. Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OVID
Previous Symbol
CUSIPN/A
Phone646-661-7661
Debt
Debt-to-Equity RatioN/A
Current Ratio5.30
Quick Ratio5.30
Price-To-Earnings
Trailing P/E Ratio-1.35
Forward P/E Ratio-2.00
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.03 per share
Price / Book2.22
Profitability
EPS (Most Recent Fiscal Year)($3.35)
Net Income$-64,800,000.00
Net MarginsN/A
Return on Equity-75.08%
Return on Assets-67.37%
Miscellaneous
Employees43
Outstanding Shares24,650,000
Market Cap$117.11 million
OptionableNot Optionable
Ovid Therapeutics (NASDAQ:OVID) Frequently Asked Questions
What is Ovid Therapeutics' stock symbol?
Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."
How were Ovid Therapeutics' earnings last quarter?
Ovid Therapeutics Inc (NASDAQ:OVID) issued its quarterly earnings results on Thursday, November, 8th. The company reported ($0.53) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.60) by $0.07. View Ovid Therapeutics' Earnings History.
When is Ovid Therapeutics' next earnings date?
What price target have analysts set for OVID?
4 analysts have issued twelve-month target prices for Ovid Therapeutics' stock. Their forecasts range from $20.00 to $27.00. On average, they anticipate Ovid Therapeutics' share price to reach $23.50 in the next year. This suggests a possible upside of 421.1% from the stock's current price. View Analyst Price Targets for Ovid Therapeutics.
What is the consensus analysts' recommendation for Ovid Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ovid Therapeutics.
Has Ovid Therapeutics been receiving favorable news coverage?
News headlines about OVID stock have been trending neutral recently, InfoTrie reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ovid Therapeutics earned a coverage optimism score of 0.5 on InfoTrie's scale. They also gave media stories about the company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the immediate future.
Who are some of Ovid Therapeutics' key competitors?
Some companies that are related to Ovid Therapeutics include Dova Pharmaceuticals (DOVA), Beyondspring (BYSI), Theratechnologies (THERF), Corium International (CORI), Aurinia Pharmaceuticals (AUPH), Prothena (PRTA), Odonate Therapeutics (ODT), Rigel Pharmaceuticals (RIGL), Xeris Pharmaceuticals (XERS), TG Therapeutics (TGTX), Progenics Pharmaceuticals (PGNX), Akebia Therapeutics (AKBA), Dermira (DERM), Kindred Biosciences (KIN) and Kura Oncology (KURA).
Who are Ovid Therapeutics' key executives?
Ovid Therapeutics' management team includes the folowing people:
- Dr. Jeremy Max Levin, Chairman & CEO (Age 65)
- Dr. Matthew J. During, Founder, Pres, Chief Scientific Officer, Director & Member of Scientific Advisory Board (Age 61)
- Ms. Lora Pike, Sr. Director of Investor Relations & PR
- Ms. Ana C. Ward Esq., M.S., M.B.A., Sr. VP, Gen. Counsel & Secretray (Age 50)
- Ms. Suzanne K. Wakamoto SPHR, SHRM-SCP, Sr. VP of HR
When did Ovid Therapeutics IPO?
(OVID) raised $80 million in an IPO on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.
Who are Ovid Therapeutics' major shareholders?
Ovid Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (4.12%), Redmile Group LLC (2.96%), Baker BROS. Advisors LP (0.90%), Granite Point Capital Management L.P. (0.45%), Dimensional Fund Advisors LP (0.32%) and JPMorgan Chase & Co. (0.22%). Company insiders that own Ovid Therapeutics stock include Douglas E Williams and Jeremy M Levin. View Institutional Ownership Trends for Ovid Therapeutics.
Which institutional investors are selling Ovid Therapeutics stock?
Which institutional investors are buying Ovid Therapeutics stock?
OVID stock was purchased by a variety of institutional investors in the last quarter, including Redmile Group LLC, Dimensional Fund Advisors LP, JPMorgan Chase & Co. and JPMorgan Chase & Co.. Company insiders that have bought Ovid Therapeutics stock in the last two years include Douglas E Williams and Jeremy M Levin. View Insider Buying and Selling for Ovid Therapeutics.
How do I buy shares of Ovid Therapeutics?
Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ovid Therapeutics' stock price today?
One share of OVID stock can currently be purchased for approximately $4.51.
How big of a company is Ovid Therapeutics?
Ovid Therapeutics has a market capitalization of $117.11 million. The company earns $-64,800,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis. Ovid Therapeutics employs 43 workers across the globe.
What is Ovid Therapeutics' official website?
How can I contact Ovid Therapeutics?
Ovid Therapeutics' mailing address is 1460 BROADWAY SUITE 15044, NEW YORK NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]
MarketBeat Community Rating for Ovid Therapeutics (NASDAQ OVID)
MarketBeat's community ratings are surveys of what our community members think about Ovid Therapeutics and other stocks. Vote "Outperform" if you believe OVID will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OVID will underperform the S&P 500 over the long term. You may vote once every thirty days.
